Philips Announces 2025 Dividend Exchange Ratio
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Source: seekingalpha
- Dividend Ratio Announcement: Philips has set the exchange ratio for the 2025 dividend at 1 new common share for every 26.9341 existing shares, based on a trading average price of EUR 22.8640 from May 27 to 29, 2026, ensuring a gross dividend of approximately EUR 0.85, highlighting the company's commitment to shareholder returns.
- New Shares Issuance: The dividend payment will result in the issuance of 19,964,655 new common shares, which will increase the company's float and is expected to positively impact market liquidity.
- Shareholder Choice: Shareholders have the option to receive dividends in shares or cash, with 43.8% opting for cash, indicating a preference for liquidity that may influence future dividend policies.
- Capital Structure Adjustment: Following the new share issuance, Philips' total issued share capital will amount to EUR 196,576,957.40, representing 982,884,787 common shares, reflecting strategic adjustments in capital management aimed at enhancing market competitiveness.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PHG?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PHG
About PHG
Koninklijke Philips NV is a Netherlands-based health technology company. The Company's segments include Personal Health businesses, Diagnosis & Treatment businesses, Connected Care businesses and Other. The Personal Health businesses segment is engaged in the health continuum, delivering integrated, connected solutions that support healthier lifestyles and those living with chronic disease as well as oral healthcare and mother and child care support. The Diagnosis & Treatment businesses segment delivers precision medicine and treatment, and therapy. The Connected Care businesses segment provides consumers, care givers and clinicians with digital solutions that facilitate care by enabling precision medicine and population health management. The Other segment comprises such items, as innovation, emerging businesses, royalties, among others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Philips Forms Strategic Alliance with WellSpan Health
- Strategic Partnership: Philips has announced a seven-year strategic alliance with WellSpan Health aimed at advancing research, innovation, and deployment of imaging and diagnostic technologies, which, while financial terms remain undisclosed, is expected to significantly enhance collaboration in the healthcare technology sector.
- Co-Development of Products: Under the agreement, Philips and WellSpan will co-develop new healthcare products and features leveraging Philips' R&D pipeline, which will not only enhance WellSpan's medical service capabilities but also drive product innovation for Philips in the healthcare market.
- Preferred Vendor Status: Philips will become WellSpan's preferred vendor for imaging modalities including CT, MRI, digital X-ray, ultrasound, and image-guided therapy systems, covering all 12 WellSpan hospitals and diagnostic imaging centers, which is anticipated to increase Philips' market share.
- Research and Innovation Strategy: The collaboration includes a research agreement and joint innovation strategy to evaluate AI and digital health tools designed to improve workflow efficiency, throughput, and cost management, thereby providing long-term business growth potential for both parties.
See More
WellSpan and Philips Forge Seven-Year Strategic Alliance
- Strategic Partnership: WellSpan and Philips have established a seven-year strategic alliance aimed at enhancing the quality and efficiency of community health services through the co-development of advanced imaging and diagnostic technologies, marking WellSpan's leadership in national healthcare innovation.
- Innovation and R&D Focus: The collaboration will focus on validating the performance of new tools and technologies, with expectations to improve throughput and workflow efficiency through AI and digital tools, helping WellSpan reclaim over 500,000 hours of workforce time annually, significantly enhancing operational efficiency.
- Long-term Commercial Agreement: Philips has been designated as WellSpan's preferred vendor across all imaging modalities, covering 12 hospitals and diagnostic imaging centers, ensuring a consistent patient experience across locations and reducing access barriers for patients.
- Transforming Future Care: By combining Philips' technological leadership with WellSpan's clinical expertise, this collaboration aims to drive measurable improvements in patient care quality and operational performance, establishing a scalable AI-driven platform that shapes the future of care delivery.
See More
Philips Secures FDA Clearance for Elevate Plus Ultrasound System
- AI Advancements: Philips' Elevate Plus has received FDA 510(k) clearance, integrating AI and automation capabilities to enhance ultrasound imaging quality and consistency, thereby enabling clinicians to conduct examinations more efficiently in high-demand settings.
- Measurement Automation: The Auto Measure Abdomen feature of Elevate Plus automates routine measurement steps using AI, reducing scanning time by up to 30% while maintaining 93% accuracy, significantly improving workflow efficiency in ultrasound operations.
- Integrated Decision Support: The Koios AI decision support system is now integrated into the EPIQ Elite and Affiniti ultrasound systems, allowing for rapid assessment of breast lesions and thyroid nodules' malignancy risk in under 2 seconds, enhancing clinical decision-making confidence and speed.
- Long-Term Value: The EPIQ Elite and Affiniti Elevate Plus systems are designed with modular technology that supports remote updates and security enhancements, ensuring ongoing adaptability and relevance to meet evolving healthcare demands.
See More
Philips Announces 2025 Dividend Exchange Ratio
- Dividend Ratio Announcement: Philips has set the exchange ratio for the 2025 dividend at 1 new common share for every 26.9341 existing shares, based on a trading average price of EUR 22.8640 from May 27 to 29, 2026, ensuring a gross dividend of approximately EUR 0.85, highlighting the company's commitment to shareholder returns.
- New Shares Issuance: The dividend payment will result in the issuance of 19,964,655 new common shares, which will increase the company's float and is expected to positively impact market liquidity.
- Shareholder Choice: Shareholders have the option to receive dividends in shares or cash, with 43.8% opting for cash, indicating a preference for liquidity that may influence future dividend policies.
- Capital Structure Adjustment: Following the new share issuance, Philips' total issued share capital will amount to EUR 196,576,957.40, representing 982,884,787 common shares, reflecting strategic adjustments in capital management aimed at enhancing market competitiveness.
See More
Philips Announces 2025 Dividend Ratio
- Dividend Ratio Announcement: Philips has set the exchange ratio for the 2025 dividend at 1 new common share for every 26.9341 existing shares, based on a volume-weighted average price of EUR 22.8640 from May 27 to 29, 2026, ensuring a gross dividend of approximately EUR 0.85.
- New Shares Issuance: The dividend payment will result in the issuance of 19,964,655 new common shares, reflecting the company's commitment to shareholder returns and indicating a stable financial position.
- Cash Election Preference: The aggregate cash election result was 43.8%, indicating a preference among some investors for cash dividends, which may influence future dividend policies and capital allocation strategies.
- Total Share Capital Impact: Following the dividend distribution, Philips' total issued share capital will amount to EUR 196,576,957.40, representing 982,884,787 common shares, demonstrating ongoing optimization of the company's capital structure.
See More
Philips and Disney Collaborate to Enhance MRI Experience for Children
- Collaboration Background: Philips and Disney announced the integration of beloved Disney animated characters and stories into Philips' MRI environment across 87 countries, aiming to help children divert their attention during imaging procedures and create a more comforting experience.
- Enhanced Child Experience: By incorporating Disney stories into the MRI setting, Philips seeks to help children feel more relaxed during scans, thereby increasing their success rate in completing exams and alleviating anxiety associated with clinical environments.
- Market Reaction: In pre-market trading on the New York Stock Exchange, Philips shares are priced at $26.15, down 1.73%, while Disney shares are at $103.79, down 0.36%, indicating a cautious market response to the collaboration.
- Strategic Significance: This partnership not only enhances the medical experience for children but may also strengthen Philips' competitive position in the medical imaging market, further expanding its influence in the global medical device sector.
See More
Philips Forms Strategic Alliance with WellSpan Health
- Strategic Partnership: Philips has announced a seven-year strategic alliance with WellSpan Health aimed at advancing research, innovation, and deployment of imaging and diagnostic technologies, which, while financial terms remain undisclosed, is expected to significantly enhance collaboration in the healthcare technology sector.
- Co-Development of Products: Under the agreement, Philips and WellSpan will co-develop new healthcare products and features leveraging Philips' R&D pipeline, which will not only enhance WellSpan's medical service capabilities but also drive product innovation for Philips in the healthcare market.
- Preferred Vendor Status: Philips will become WellSpan's preferred vendor for imaging modalities including CT, MRI, digital X-ray, ultrasound, and image-guided therapy systems, covering all 12 WellSpan hospitals and diagnostic imaging centers, which is anticipated to increase Philips' market share.
- Research and Innovation Strategy: The collaboration includes a research agreement and joint innovation strategy to evaluate AI and digital health tools designed to improve workflow efficiency, throughput, and cost management, thereby providing long-term business growth potential for both parties.
See More
WellSpan and Philips Forge Seven-Year Strategic Alliance
- Strategic Partnership: WellSpan and Philips have established a seven-year strategic alliance aimed at enhancing the quality and efficiency of community health services through the co-development of advanced imaging and diagnostic technologies, marking WellSpan's leadership in national healthcare innovation.
- Innovation and R&D Focus: The collaboration will focus on validating the performance of new tools and technologies, with expectations to improve throughput and workflow efficiency through AI and digital tools, helping WellSpan reclaim over 500,000 hours of workforce time annually, significantly enhancing operational efficiency.
- Long-term Commercial Agreement: Philips has been designated as WellSpan's preferred vendor across all imaging modalities, covering 12 hospitals and diagnostic imaging centers, ensuring a consistent patient experience across locations and reducing access barriers for patients.
- Transforming Future Care: By combining Philips' technological leadership with WellSpan's clinical expertise, this collaboration aims to drive measurable improvements in patient care quality and operational performance, establishing a scalable AI-driven platform that shapes the future of care delivery.
See More
Philips Secures FDA Clearance for Elevate Plus Ultrasound System
- AI Advancements: Philips' Elevate Plus has received FDA 510(k) clearance, integrating AI and automation capabilities to enhance ultrasound imaging quality and consistency, thereby enabling clinicians to conduct examinations more efficiently in high-demand settings.
- Measurement Automation: The Auto Measure Abdomen feature of Elevate Plus automates routine measurement steps using AI, reducing scanning time by up to 30% while maintaining 93% accuracy, significantly improving workflow efficiency in ultrasound operations.
- Integrated Decision Support: The Koios AI decision support system is now integrated into the EPIQ Elite and Affiniti ultrasound systems, allowing for rapid assessment of breast lesions and thyroid nodules' malignancy risk in under 2 seconds, enhancing clinical decision-making confidence and speed.
- Long-Term Value: The EPIQ Elite and Affiniti Elevate Plus systems are designed with modular technology that supports remote updates and security enhancements, ensuring ongoing adaptability and relevance to meet evolving healthcare demands.
See More
Philips Announces 2025 Dividend Exchange Ratio
- Dividend Ratio Announcement: Philips has set the exchange ratio for the 2025 dividend at 1 new common share for every 26.9341 existing shares, based on a trading average price of EUR 22.8640 from May 27 to 29, 2026, ensuring a gross dividend of approximately EUR 0.85, highlighting the company's commitment to shareholder returns.
- New Shares Issuance: The dividend payment will result in the issuance of 19,964,655 new common shares, which will increase the company's float and is expected to positively impact market liquidity.
- Shareholder Choice: Shareholders have the option to receive dividends in shares or cash, with 43.8% opting for cash, indicating a preference for liquidity that may influence future dividend policies.
- Capital Structure Adjustment: Following the new share issuance, Philips' total issued share capital will amount to EUR 196,576,957.40, representing 982,884,787 common shares, reflecting strategic adjustments in capital management aimed at enhancing market competitiveness.
See More
Philips Announces 2025 Dividend Ratio
- Dividend Ratio Announcement: Philips has set the exchange ratio for the 2025 dividend at 1 new common share for every 26.9341 existing shares, based on a volume-weighted average price of EUR 22.8640 from May 27 to 29, 2026, ensuring a gross dividend of approximately EUR 0.85.
- New Shares Issuance: The dividend payment will result in the issuance of 19,964,655 new common shares, reflecting the company's commitment to shareholder returns and indicating a stable financial position.
- Cash Election Preference: The aggregate cash election result was 43.8%, indicating a preference among some investors for cash dividends, which may influence future dividend policies and capital allocation strategies.
- Total Share Capital Impact: Following the dividend distribution, Philips' total issued share capital will amount to EUR 196,576,957.40, representing 982,884,787 common shares, demonstrating ongoing optimization of the company's capital structure.
See More
Philips and Disney Collaborate to Enhance MRI Experience for Children
- Collaboration Background: Philips and Disney announced the integration of beloved Disney animated characters and stories into Philips' MRI environment across 87 countries, aiming to help children divert their attention during imaging procedures and create a more comforting experience.
- Enhanced Child Experience: By incorporating Disney stories into the MRI setting, Philips seeks to help children feel more relaxed during scans, thereby increasing their success rate in completing exams and alleviating anxiety associated with clinical environments.
- Market Reaction: In pre-market trading on the New York Stock Exchange, Philips shares are priced at $26.15, down 1.73%, while Disney shares are at $103.79, down 0.36%, indicating a cautious market response to the collaboration.
- Strategic Significance: This partnership not only enhances the medical experience for children but may also strengthen Philips' competitive position in the medical imaging market, further expanding its influence in the global medical device sector.
See More
